Entrada Therapeutics, Inc. Common Stock (TRDA) Stock Price, Quote & AI Analysis

Live TRDA stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Entrada Therapeutics, Inc. Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for Entrada Therapeutics, Inc. Common Stock (TRDA), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

T
TRDA
Entrada Therapeutics, Inc. Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
11.400000
High
12.080000
Low
11.400000
Volume
194,772
VWAP
-
Market Cap
$437,228,014.08
52W Range
$4.93 - $14.27
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Feb 25, 2026 Q4
After Hours
EPS Estimate: $-0.9976
Revenue Estimate: $14,163,720.00
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Entrada Therapeutics, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Entrada Therapeutics, Inc. Common Stock Overview

Company information

Company Overview

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company’s Endosomal Escape Vehicle (EEV) therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The company’s oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. Entrada Therapeutics was founded by Dehua Pei in 2016 and is headquartered in Boston, MA.

Company Details
Market Cap
$452.90M
Shares Outstanding
38,219,230
Weighted Shares Outstanding
38,219,232
CEO
Dipal Doshi
Address
ONE DESIGN CENTER PLACE, BOSTON, MA, 02210
Employees
183
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Entrada Therapeutics, Inc. Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...